Laboratory Diagnosis of Monkeypox Virus: Current and Upcoming Tests

Home Resources LIMS Webinars Laboratory Diagnosis of Monkeypox Virus: Current and Upcoming Tests
Diagnostics LIMS for Monkeypox Virus Testing Labs

January 25, 2023


Monkeypox virus is an orthopoxvirus and causes a disease with symptoms similar to smallpox but less severe. Transmission between humans is possible. Monkeypox virus infection can be transmitted through contact with bodily fluids, internal mucosal surfaces, skin lesions in the mouth or throat, respiratory droplets, and contaminated objects. It is difficult for physicians unfamiliar with monkeypox-like illnesses to differentiate it from other viral, bacterial, or other conditions.

Nonspecific clinical presentations, lesions, and inflammation of the pharyngeal mucosa have been reported; these symptoms can be seen in other viral and non-viral infections. Therefore, accurate laboratory diagnosis of the disease while following all biosafety measures is of paramount importance to arrest the spread of infection. A Laboratory Information Management System (LIMS) helps streamline and automate the complete sample lifecycle in a clinical diagnostic laboratory. Furthermore, a LIMS for diagnostics helps overcome all testing, reporting, regulatory, and data management challenges of laboratories while enhancing their efficiency and reducing the turnaround time.

When: January 25, 2023, at 9 AM PST (5 P.M. BST)

Key Takeaways:

  • An overview of the monkeypox virus and its characteristics from the current outbreak.
  • The latest guidelines and recommendations for testing.
  • How a LIMS helps automate and streamline operations in clinical diagnostic laboratories.

Who Should Watch

Recommended attendees include laboratory managers, directors, quality managers, and technicians of clinical diagnostic laboratories.


Please fill the form to watch the webinar

I give consent to provide my registration information to CloudLIMS. For details on our privacy policy, please click privacy policy.

*Indicates mandatory

Martha Hernandez

Martha Hernández

Martha is a chemist with expertise in diverse areas of analytical chemistry. She had worked as an analyst at a licensed 3rd party analytical laboratory where she focused on developing and validating analytical methods for bioequivalence studies. Later, she served as a quality control expert in the analytical domain and as a monitor in clinical trials. Her interest in the clinical industry led her to be a part of two of the biggest hospitals in Mexico where she gained expertise in hematology, microbiology, and blood banking. Later, she became a member of the team of forensic chemical experts and started working from day one as a specialist in narcotics and drugs. This enabled her to gain rich experience in GC-MS, FTIR, HPLC-MS/MS, ICP-MS, and other analytical techniques for the separation, detection, and quantification of different molecules such as cannabinoids. She had participated in multiple oral trials defending her legal opinions and worked as an expert consultant. She had worked on the synthesis of small molecules for testing them on multi-drug resistant bacteria and mycobacteria, further developing her analytical skills in column chromatography, thin-layer chromatography, microbiology, and compound elucidation by NMR and HRMS. She carried out a research stay at the University of Barcelona with the organic synthesis team. She had also worked on natural products in France and presented her work at conferences in the USA and France. She received awards and accolades for her exceptional work. She has participated in several conferences as a moderator as well.

Martha holds a bachelor’s degree in Clinical Chemistry from the Faculty of Medicine UANL and a master’s degree in Pharmacy from the Faculty of Chemical Sciences UANL, Mexico.